1. Information, allocations, multi-countries and transition
LATIN AMERICA AND CARIBBEAN REGION
Information, allocations, multi-countries and transition
13 November 2017

2. LAC GENERAL OVERVIEW (past and future)
Overall we have 22 countries and 46 individual country grants in the new allocation – (consolidation of 4 countries into MCC ( HIV/TB 4 countries), and other into HIV/TB 3 countries ) – not including any regional grants
Allocations vs
DISEASE
3 YEAR ALLOCATION EQUIVALENT
PROJECTED EXPENDITURE
ALLOCATIONS
% prior allocation
% prior projected expenditure
HIV
270,352,859
235,140,927
199,414,981
73.76%
84.81% TB
82,658,970.25
69,647,857.84
55,619,016
67.29%
79.86%
Malaria
71,324,108
61,452,081
47,206,031
66.19%
76.82%
HIV/TB
16,700,000
15,500,000
9,952,565
59.60%
64.21%
TOTAL
441,035,937
381,740,866
312,192,593.00
70.79%
81.78%

4. Allocation comparison
Country
Disease
Currency
Allocations
spend to end of grant
Country total 17-19
% of prior allocation
% prior spend
Belize
Total
USD
3,400,000
3,300,000
1,916,278
56.36%
58.07%
Bolivia (Plurinational State)
32,632,236
27,200,000
18,632,258
57.10%
68.50%
Colombia
14,600,000
11,800,000
10,014,581
68.59%
84.87%
Costa Rica
3,700,000
3,160,005
2,120,098
57.30%
67.09%
Cuba
16,400,000
18,400,000
13,253,226
80.81%
72.03%
Dominican Republic
37,400,000
32,054,698
20,488,796
54.78%
63.92%
Ecuador
12,259,984
9,227,431
5,328,421
43.46%
57.75%
El Salvador
28,300,000
28,900,000
18,724,557
66.16%
64.79%
Guatemala
55,600,000
46,702,701
31,985,369
57.53%
68.49%
Guyana
13,920,015
7,300,000
6,105,356
43.86%
83.64%
Haiti
91,011,032
78,200,000
105,712,929
116.15%
135.18%
Honduras
30,694,820
25,600,000
18,124,919
59.05%
70.80%
Jamaica
14,400,000
13,470,131
9,930,638
68.96%
73.72%
Multicountry Carribbean3
4,000,000
3,550,000
88.75%
Nicaragua
30,570,902
28,400,000
18,995,233
62.14%
66.88%
Panama
5,800,000
5,400,000
2,685,892
46.31%
49.74%
Paraguay
19,700,000
15,624,065
7,348,288
37.30%
47.03%
Peru
20,846,948
17,951,835
13,463,877
64.58%
75.00%
Suriname
5,050,000
3,811,877
65.72%
75.48%
381,740,866
312,192,593
70.79%
81.78%

5. Max.3 years funding to implement transition activities
Co-Financing requirements along the development continuum work towards enhancing program sustainability and eventual transitions
LMICs
with low/moderate
disease burden
/ UMICs
LMICs
with high disease
burden
Fully transitioned
Ineligible
LICs
“Final Grant”
Focus on long-term sustainability planning by supporting the development of robust national health strategies, disease specific strategic plans and health financing strategies
Focus on sustainability and transition preparedness, particularly for countries projected to transition*
Max.3 years funding to implement transition activities
Haiti (HIV, TB,malaria)
Bolivia (HIV, TB)
El Salvador (HIV)
Guatemala (HIV)
Honduras (HIV)
Nicaragua (HIV)
Guyana (HIV, TB, M)
UMIC
Belize (HIV)
Colombia (HIV)
Costa Rica (HIV)*
Dominican Republic (HIV)
Ecuador (HIV)
Jamaica (HIV)
Paraguay (HIV)
Peru (HIV, TB)
Suriname (HIV and malaria)
LMIC with L/M DB
Bolivia (malaria)**
El Salvador (TB, malaria)*
Guatemala (TB, malaria)**
Honduras (TB, malaria)
Nicaragua (TB, malaria)
Cuba (HIV)
Belize (TB)
Dominican Republic (TB)
Paraguay (TB and malaria)
Suriname (TB)
Panama (TB and HIV)
3 components
9 components
20 components
*(3 projected transitions in allocation) ** (3 projected transitions in )
8 components
3 projected transitions in :

6. Who is transitioning now, and who is projected to transition?

7. Summary: transition components
FINAL GRANT
Grant
End grant date
TRA status
TRA work-plan
Funding request
Others
Cuba (HIV)
31-Dec-2017
Completed W1
Autodiagnosis completed
Belize (TB)
31-Dec-2018
On-going
To be developed
W5 (April18)
TRA also includes HIV;
(HIV/TB funding request)
Dom. Republic (TB)
W5 (April 18)
Separate HIV/ TB funding request

8. Countries prioritized as UMI, and LMI with moderate disease burden where work on transition needs to begin

9. Countries/components transition 3 to 6 and 9 years

10. Components that remain depending on trends and resources as per eligibility today

11. Status - new allocation submissions

12. Funding from different allocation periods can no longer overlap
Unlike the transition period/last replenishment, existing funding does not carry over into next allocation cycle

13. Allocation Utilization Period
Any end-date revision (formerly known as ‘extensions’) will use funding & time from the next allocation period
IP1
End date revision to IP 1
IP2
6 months
2.5 years
Original IP/grant end date 2M 8M
Funds
Time
Example:
Allocation Utilization Period
Start date of new IP/grant
Grant end-date revisions to the existing implementation period will be deducted from the next allocation in funds and time
Unused funds at the original grant end date will be used for portfolio optimization investments and to top-up grants with high absorption levels and good performance
In order to avoid this, countries can still make program revisions to their grants up to 14 months before the end date of grant implementation to improve absorption levels
e.g. an IP of only 2.5 years using 8M out of 10M country allocation
SPECIFIC INTERNAL GUIDANCE IS BEING PREPARED FOR COUNTRY TEAMS ON THIS ISSUE

14. Multicountry approach
As per Board Decision GF/B36/04 and on technical partner recommendation funding is to be directed towards multicountry approaches for the following purpose: “to target a limited number of key, strategic multicountry priorities deemed critical to meet the aims of the Strategy and not able to be addressed through country allocations alone”
Malaria
US$ 145/6M LAC
Tuberculosis
US$ 65 M/ 4.5 M LAC
HIV
US$ 50 M/17M LAC
Regional added value and complementarity to the national grants.
MC has to complimentary to the national grants/allocations, and not duplicate the national efforts being covered in the national allocations.

15. Multi- county for TB and Malaria
TB – 4.5 million for a new grant integration of CSO into the reposnse as grants transition - will come with others in Window 6, TORs to be launched in April
Malaria – 6 Million – went through Window 3 , Blended finance with IDB, Gates (CHAI) , GF, PAHO , COMISCA , RCM-
To help accelerate the elimination of malaria in Central America, the IDB together with all key partners and countries is setting up a blended finance facility (as part of the Regional Malaria Elimination Initiative – RMEI) to help strengthen technical assistance, harmonize donor and technical partner Malaria elimination efforts.

16. Approved Multicountry Allocation US$ millions
Regions selected for MC approach for HIV: Sustainability of services for key populations
Regions
Approved Multicountry Allocation US$ millions
EECA 13
LAC 17
SE Asia
12.5
MENA
7.5
Total 50
Summary: Out of the 200 mi on HIV from the catalytic investment, 50 mill is for MC HIV, and from this 17 mil are for LAC.
No African regions are included in this distribution. The priority for MC on HIV was defined for sustainability for KP, referring to the portfolios preparing or gearing up for transition out of GF financing.

17. Strategic Priority: Sustainability of services for key populations in LAC region
Operational priority: RFP based on consultation
Upper Ceiling Allocation: US$ 17,000,000
Estimated number of grants: 1-2 in Latin America and 1 in Caribbean region
Key population scope: To be defined based on further consultation.
Geographical Focus: To be defined based on consultation process. Focus on the needs of sub-regions: Caribbean, Central America, South America.
Aim: Strategic support for development, innovative delivery of services and sustainability of community-led service delivery and monitoring, and support for regional advocacy, address legal barriers, also laying the groundwork for continuity of these services as part of a transition process*. TBD based on consultation process.
*This is based on the board document on catalytic investment.